1. BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (June 2017) Authors: Trotman, J.; Opat, S.; Marlton, P.; Gottlieb, D.; Simpson, D.; Cull, G.; Ritchie, D.; Verner, E.; Ratnasingam, S.; Anderson, M.; Wood, P.; Wang, L.; Xue, L.; Hedrick, E.; Huang, J.; Hilger, J.; Seymour, J.F.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY. (June 2017) Authors: Seymour, J.F.; Opat, S.; Cull, G.; Trotman, J.; Gottlieb, D.; Simpson, D.; Marlton, P.; Anderson, M.; Ku, M.; Ritchie, D.S.; Ratnasingam, S.; Augustson, B.; Kim, W.; Wang, L.; Xue, L.; Hilger, J.; Huang, J.; Hedrick, E.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P687: A PHASE 1 STUDY WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 AS MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES: PRELIMINARY DATA. (23rd June 2022) Authors: Opat, S.; Cheah, C. Y.; Lasica, M.; Verner, E.; Browett, P. J.; Chan, H.; Soumerai, J. D.; González Barca, E.; Hilger, J.; Fang, Y.; Huang, J.; Simpson, D.; Tam, C. S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗